We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data
Read MoreHide Full Article
Incyte Corporation (INCY - Free Report) announced pooled analysis of five-year data from two phase III studies – COMFORT-I and COMFORT-II – on Jakafi, which support previously published overall survival (OS) advantage observed in patients with myelofibrosis (MF).
A look at Incyte’s share price movement so far this year shows that the stock has outperformed the Zacks classified Medical-Biomed/Genetics industry. Though the stock’s price declined 6% in the year-to-date period, it compared favorably to the 25.6% fall for the industry.
Coming back to the latest news, the two phase III studies evaluated the safety and efficacy of Jakafi in patients (n=528) with intermediate-2 or high-risk primary MF, post-polycythemia vera (PV) MF, or post-essential thrombocythemia MF.
Findings demonstrated that prolonged survival for patients with intermediate-2 or high-risk MF revealed a 30% reduction in the risk of death in patients who received Jakafi compared to the control groups (best available therapy or placebo). In addition, Jakafi showed OS advantage in various patient subgroups including age, sex, disease type, risk status, JAK2V617F mutation status, baseline spleen length, anemia, white blood cell count, and platelet count.
Note that Jakafi is approved in the U.S. for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. It is also indicated for the treatment of patients with intermediate or high-risk MF, including primary MF, post-PV MF, and post-essential thrombocythemia MF. While Incyte markets the drug in the U.S., Novartis AG (NVS - Free Report) is responsible for its commercialization in the ex-U.S. market.
In the first nine months of 2016, Jakafi generated sales of $615.3 million, up 47% year over year. Jakafi revenues are expected in the range of $850–$855 million in 2016.
We remind investors that in Sep 2016, the company announced that Jakafi has been included as a recommended treatment for MF in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Inclusion in the Guidelines will help make healthcare providers aware of Jakafi’s benefits and aid treatment decisions for patients with MF. This also underscores the important and long-term clinical benefits seen in patients treated with Jakafi.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 7.7% year to date.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016, while its earnings estimates have increased from 16 cents to 22 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average positive surprise of 56.65%. Its share price has surged 67.6% year to date.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data
Incyte Corporation (INCY - Free Report) announced pooled analysis of five-year data from two phase III studies – COMFORT-I and COMFORT-II – on Jakafi, which support previously published overall survival (OS) advantage observed in patients with myelofibrosis (MF).
A look at Incyte’s share price movement so far this year shows that the stock has outperformed the Zacks classified Medical-Biomed/Genetics industry. Though the stock’s price declined 6% in the year-to-date period, it compared favorably to the 25.6% fall for the industry.
Coming back to the latest news, the two phase III studies evaluated the safety and efficacy of Jakafi in patients (n=528) with intermediate-2 or high-risk primary MF, post-polycythemia vera (PV) MF, or post-essential thrombocythemia MF.
Findings demonstrated that prolonged survival for patients with intermediate-2 or high-risk MF revealed a 30% reduction in the risk of death in patients who received Jakafi compared to the control groups (best available therapy or placebo). In addition, Jakafi showed OS advantage in various patient subgroups including age, sex, disease type, risk status, JAK2V617F mutation status, baseline spleen length, anemia, white blood cell count, and platelet count.
Note that Jakafi is approved in the U.S. for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. It is also indicated for the treatment of patients with intermediate or high-risk MF, including primary MF, post-PV MF, and post-essential thrombocythemia MF. While Incyte markets the drug in the U.S., Novartis AG (NVS - Free Report) is responsible for its commercialization in the ex-U.S. market.
In the first nine months of 2016, Jakafi generated sales of $615.3 million, up 47% year over year. Jakafi revenues are expected in the range of $850–$855 million in 2016.
We remind investors that in Sep 2016, the company announced that Jakafi has been included as a recommended treatment for MF in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Inclusion in the Guidelines will help make healthcare providers aware of Jakafi’s benefits and aid treatment decisions for patients with MF. This also underscores the important and long-term clinical benefits seen in patients treated with Jakafi.
INCYTE CORP Price
INCYTE CORP Price | INCYTE CORP Quote
Incyte currently has Zacks Rank #3 (Hold).
Key Picks in the Sector
A couple of better-ranked stocks in the health care sector include Cambrex Corporation and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 7.7% year to date.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016, while its earnings estimates have increased from 16 cents to 22 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average positive surprise of 56.65%. Its share price has surged 67.6% year to date.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>